»5 Minute Wrap Up by Equitymaster

On This Day - 24 JULY 2015
Are you buying stocks at an auction?

In this issue:
» India Inc's pricey amongst the priciest
» Pharma majors' ambitious global foray
» How are companies using their 'crude' savings?
» ..and more!

Buy stocks like groceries and not like perfumes. This is possibly the simplest way to understand what value investing is all about. And coming from none other than the grandfather of value investing, Benjamin Graham, this is the most repeated sermon on the subject. However, for a lay investor, one look at the valuations today, will make him wonder what was Graham thinking when he said this! For there is so much money chasing so few good businesses that valuations have gone through the roof. And unless patience is one of your biggest virtues, you can forget about seeing the sought after stocks in your portfolio.

Over the years, investors have realized that amongst the thousands of listed companies, there is just a handful that has successfully multiplied investor wealth. And hence there is no reluctance in buying the most coveted 'trophy' stocks at auction-like prices.

Now, the rally in stock market valuations from 2003 till date has had three legs to it. The first one of course is growth in earnings as Indian companies displayed their ability to compete and acquire companies globally. The second was the huge influx in foreign capital with interest rates overseas heading to zero. And the third was valuation re-rating as emerging economies like India stood out for relatively higher growth rates. Barring the temporary correction in 2008 and 2009, the upward rise in valuations of the best businesses has been a one way ride. And even if the earnings growth takes a backseat, as long as the foreign funds keep trickling in, the most sought after business could enjoy their premium.

The current valuations of some of the best business seem to have no relevance to their past or future earnings growth. Rather they seem to be driven by the desire of investors to own the trophy stocks. And hence forget about groceries and perfumes, investors seem to be buying such stocks with an auction like mindset.

The assumption that the great businesses will always find takers at any price has driven their valuations to irrational levels. In fact some of the most consistent and fundamentally sound companies in India are currently valued at multiples that are amongst the highest globally. Kotak Mahindra Bank, one of the most expensive financial entities in India trades at 2.5 times the valuations of one of the world's best bank Wells Fargo. HUL too trades at almost 2.5 times parent Unilever's valuations. The multiple for Asian Paints is double that for global paint giant PPG. And in fact, if higher growth in the Asian region is the rationale for the valuations, India companies are leaving even the Chinese behemoths behind. The stocks of Eicher Motors and L&T seem to offering their Chinese auto and infrastructure counterparts stiff competition in valuations. This is even though the Chinese companies are much larger in size.

Priciest amongst the pricey?
 P/E or P/BV*
Kotak Bank 4.7
Wells Fargo 1.8
HUL 45.7
Unilever 18.7
Eicher Motors 103.1
Dongfeung Auto 108.4
Asian Paints 53.8
PPG 26.2
L&T 34.6
China Railway 12.5
*As on 24th July 2015
Data source: Equitymaster, Yahoo Finance, ycharts.com

So should you give in to the temptation of bidding for the trophy stocks at stock market auctions?

Well, buying stocks with auction like mindset may serve well in terms of helping you show off your portfolio to your friends and family. But it is rather unlikely that such a mindset will help you create real wealth over the long term.

And hence instead of fretting over the lost opportunity to bag such stocks when they were cheap, you would rather be on the lookout for the best businesses in the making. Even if just a few of your stocks bought with safety in valuations turn out to be winners, you could well be the owner of some trophy stocks several years down the line. That too without participating in the auction!

Do you approve of buying the most coveted stocks with auction like mindset? Let us know your comments or share your views in the Equitymaster Club.

--- Advertisement ---
Mark The 15th For High Potential Stocks...

On or around the 15th of every month, we reveal one high-potential small cap to our subscribers.

Some such small cap stocks from the past have given returns like 250% in 2 years, 123% in just 3 months, 288% in 2 years 5 months and more...

And we have been doing this for more than 7 years now!

So click here to see how YOU too could make the 15th a memorable and profitable date for you... every single month!


 Chart of the day
Talking about valuations, Indian pharma companies certainly deserve a mention. For they were amongst the biggest gainers in 2014. And it seems there is reason for some of the stocks to continue commanding their premium. The Indian pharma majors have been on an acquisition spree over the past few years. Lupin's latest buyout of Gavis Pharma is one of the biggest buyouts by an Indian company in the international market. The global generics market in recent times has become one that is characterized by intense competition, growing stringent regulations and price erosion. Hence, the companies are scrambling to acquire scale to have that 'edge' over their peers in terms of bargaining power and pricing.

Growing M&A activity in the pharma space

The large ticket acquisition provides the much needed scale to survive the tough conditions in the generics market. But one also needs to keep in mind the aftermath of these acquisitions. The companies that embark their ambitious expansion plans at the cost of high leverage could cause disarray in its financials. Other than this, are the integration issues that companies face. Ranbaxy's acquisition by Sun Pharma is the case in point here.

Further, these global acquisitions certainly bring in the country risks. The classic example here is of Dr Reddy's acquisition of Betapharm. Betapharm at the time of acquisition was the fourth largest generics company in Germany. The subsequent changes in the German generics market had an adverse impact on Betapharm. Dr Reddy is still struggling to grow in this market. At the end of the day, what matters is how the company is able to derive value from the acquisition. And augment the overall performance despite the slew of challenges in the medium term.

Meanwhile, low crude prices continue to be a windfall for India Inc. Perhaps the government was the biggest beneficiary of the steep fall in international crude prices as it helped contain the current account deficit (CAD) as well as cap the subsidy burden. However, there are many sectors which seem to be taking advantage from this plummeting crude price. The FMCG sector is the case in point here.

The input costs of various FMCG companies that have crude as input for manufacturing soaps etc, have come down. Some of these companies have been utilizing these incremental savings for R&D purposes. The trend is already visible for various leading players viz; Britannia, GlaxoSmithKline Consumer, Marico, ITC and others. ITC has already increased its expenditure as much as 48% in the year gone by. While the current fall in crude is giving these companies an extra cushion in margins, the R&D spend is likely to strengthen their product pipeline. But given the volatility in the crude prices one cannot expect this trend to last long. Hence, companies that can stand relatively resilient when the cycle reverses should be the preferred bets.

After opening on a weak note, the Indian stock markets have continued to decline. At the time of writing, the BSE-Sensex was trading lower by around 177 points. Selling pressure was largely seen in realty and auto stocks. Stocks from the consumer durables space were, however, trading strong. Both the midcap and smallcap indices also were marginally down, with the S&P BSE Midcap and S&P BSE Smallcap indices down by about 0.15% each.

 Today's investing mantra
"The highest stock market prices relative to intrinsic business value are given to companies whose managers have demonstrated their unwillingness to issue shares at any time on terms unfavorable to the owners of the business" - Warren Buffett.

Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537.

An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes.

There are no outstanding litigations against the Company, it subsidiaries and its Directors.

For the terms and conditions for research reports click here.

Details of Associates are available here.

  1. 'subject company' is a company on which a buy/sell/hold view or target price is given/changed in this Research Report
  2. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any financial interest in the subject company.
  3. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have actual/beneficial ownership of one percent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.
  4. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any other material conflict of interest at the time of publication of the research report.
  1. Neither Equitymaster nor it's Associates have received any compensation from the subject company in the past twelve months.
  2. Neither Equitymaster nor it's Associates have managed or co-managed public offering of securities for the subject company in the past twelve months.
  3. Neither Equitymaster nor it's Associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  4. Neither Equitymaster nor it's Associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  5. Neither Equitymaster nor it's Associates have received any compensation or other benefits from the subject company or third party in connection with the research report.
  1. The Research Analyst has not served as an officer, director or employee of the subject company.
  2. Equitymaster or the Research Analyst has not been engaged in market making activity for the subject company.
Definitions of Terms Used:
  1. Buy recommendation: This means that the investor could consider buying the concerned stock at current market price keeping in mind the tenure and objective of the recommendation service.
  2. Hold recommendation: This means that the investor could consider holding on to the shares of the company until further update and not buy more of the stock at current market price.
  3. Buy at lower price: This means that the investor should wait for some correction in the market price so that the stock can be bought at more attractive valuations keeping in mind the tenure and the objective of the service.
  4. Sell recommendation: This means that the investor could consider selling the stock at current market price keeping in mind the objective of the recommendation service.
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.

Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement

Disclosure & Disclaimer: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. The Author does not hold any shares in the company/ies discussed in this document. Equitymaster may hold shares in the company/ies discussed in this document under any of its other services.

This document is confidential and is supplied to you for information purposes only. It should not (directly or indirectly) be reproduced, further distributed to any person or published, in whole or in part, for any purpose whatsoever, without the consent of Equitymaster.

This document is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity, who is a citizen or resident or located in any locality, state, country or other jurisdiction, where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject Equitymaster or its affiliates to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, Canada or the European Union countries, the same may be ignored.

This document does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Our research recommendations are general in nature and available electronically to all kind of subscribers irrespective of subscribers' investment objectives and financial situation/risk profile. Before acting on any recommendation in this document, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the securities referred to in this material and the income from them may go down as well as up, and subscribers may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. Information herein is believed to be reliable but Equitymaster and its affiliates do not warrant its completeness or accuracy. The views/opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time without notice. This document should not be construed as an offer to sell or solicitation of an offer to buy any security or asset in any jurisdiction. Equitymaster and its affiliates, its directors, analyst and employees will not be responsible for any loss or liability incurred to any person as a consequence of his or any other person on his behalf taking any decisions based on this document.

As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407